Prognostic factors in metastatic gastric carcinoma

Exp Oncol. 2019 Jun;41(2):173-175. doi: 10.32471/exp-oncology.2312-8852.vol-41-no-2.13283.

Abstract

Although its incidence has declined over last half-century, gastric cancer remains the second most frequent cause of cancer death in the world. The ⅔ of the patients are metastatic at diagnosis. The current study aimed to identify some determinants of survival in patients with metastatic gastric carcinoma.

Materials and methods: It was a retrospective study that involved 49 patients treated with palliative chemotherapy between January 2000 and December 2010. Factors included: age, gender, performance status, metastatic diagnosis onset (at diagnosis or later); specific metastatic sites, number of metastatic localizations, response to chemotherapy, and hemoglobin rate.

Results: In univariate analysis, factors associated to a better survival were: metastasis at diagnosis, good performance status, response to chemotherapy and single metastatic site. Independent factors in multivariate analysis were: metastasis at diagnosis and single metastatic site.

Conclusion: Our study confirmed many determinants on survival described in the literature.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cisplatin / therapeutic use
  • Combined Modality Therapy
  • Female
  • Fluorouracil / therapeutic use
  • Gastrectomy
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis / pathology*
  • Prognosis
  • Retrospective Studies
  • Stomach Neoplasms / mortality
  • Stomach Neoplasms / pathology*
  • Stomach Neoplasms / therapy*

Substances

  • Antineoplastic Agents
  • Cisplatin
  • Fluorouracil